Cipla (CIPLA) Aktienübersicht
Cipla Limited ist zusammen mit seinen Tochtergesellschaften in der Herstellung, der Entwicklung, dem Verkauf und dem Vertrieb von pharmazeutischen Produkten in Indien, den Vereinigten Staaten, Südafrika und international tätig. Mehr Details
| Schneeflocken-Punktzahl | |
|---|---|
| Bewertung | 1/6 |
| Künftiges Wachstum | 1/6 |
| Vergangene Leistung | 2/6 |
| Finanzielle Gesundheit | 6/6 |
| Dividenden | 4/6 |
CIPLA Community Fair Values
Create NarrativeSee what 43 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cipla Limited Wettbewerber
Preisentwicklung & Leistung
| Historische Aktienkurse | |
|---|---|
| Aktueller Aktienkurs | ₹1,458.20 |
| 52-Wochen-Hoch | ₹1,673.00 |
| 52-Wochen-Tief | ₹1,165.70 |
| Beta | 0.11 |
| 1 Monat Veränderung | 4.25% |
| 3 Monate Veränderung | 22.29% |
| 1 Jahr Veränderung | -3.64% |
| 3 Jahre Veränderung | 42.87% |
| 5 Jahre Veränderung | 51.93% |
| Veränderung seit IPO | 45,088.42% |
Aktuelle Nachrichten und Updates
CIPLA: Fair Outlook As Respiratory Diagnostics And US Generics Pipeline Evolve
Analysts have marginally reduced their fair value estimate for Cipla, trimming the price target from about ₹1,460 to roughly ₹1,457 as they fine-tune assumptions on long term profit margins and forward P/E multiples, while keeping core growth expectations broadly unchanged. What’s in the News for Cipla Cipla launched Ciposcillo, an advanced oscillometer for early detection of respiratory diseases such as COPD and asthma, built on US FDA cleared technology and approved by India’s CDSCO.CIPLA: Fair Outlook As New CEO And Respiratory Portfolio Changes Take Shape
Analysts have raised their price target on Cipla by about ₹30 to ₹1,459.57, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple, alongside a marginally higher discount rate. What's in the News Cipla launched Ciposcillo, an advanced oscillometer for early detection of respiratory diseases like COPD and asthma.Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...Recent updates
CIPLA: Fair Outlook As Respiratory Diagnostics And US Generics Pipeline Evolve
Analysts have marginally reduced their fair value estimate for Cipla, trimming the price target from about ₹1,460 to roughly ₹1,457 as they fine-tune assumptions on long term profit margins and forward P/E multiples, while keeping core growth expectations broadly unchanged. What’s in the News for Cipla Cipla launched Ciposcillo, an advanced oscillometer for early detection of respiratory diseases such as COPD and asthma, built on US FDA cleared technology and approved by India’s CDSCO.CIPLA: Fair Outlook As New CEO And Respiratory Portfolio Changes Take Shape
Analysts have raised their price target on Cipla by about ₹30 to ₹1,459.57, citing updated assumptions for revenue growth, profit margins and a slightly lower future P/E multiple, alongside a marginally higher discount rate. What's in the News Cipla launched Ciposcillo, an advanced oscillometer for early detection of respiratory diseases like COPD and asthma.Cipla Limited Just Missed EPS By 7.0%: Here's What Analysts Think Will Happen Next
Cipla Limited ( NSE:CIPLA ) missed earnings with its latest annual results, disappointing overly-optimistic...CIPLA: New CEO, US Respiratory Launch And Biologics Venture Will Steady Outlook
Analysts now place Cipla's fair value at ₹1,429.83, a small move from ₹1,427.58. This reflects refreshed assumptions around revenue growth, profit margin and future P/E expectations.CIPLA: New CEO And Biologics Venture Will Support Stronger Outlook
Cipla's analyst fair value estimate has been adjusted slightly from about ₹1,436.58 to ₹1,427.58, reflecting updated assumptions around revenue growth, profit margins and future P/E expectations according to analysts. What's in the News Cipla plans a board meeting on May 13, 2026, to review standalone and consolidated audited financial results for the quarter and year ended March 31, 2026, and to consider a final dividend for the year, if any (company filing).CIPLA: New CEO And Biologics Venture Will Support Stronger Long Term Outlook
Analysts have trimmed Cipla's implied fair value price target slightly from ₹1,446.31 to ₹1,436.58, reflecting updated views on its revenue growth, profit margin outlook, and future P/E assumptions. What's in the News A board meeting is scheduled for 19 Mar 2026 to consider appointing P R Ramesh, Lead Independent Director, as Vice Chairman, and to take up the planned exit of Independent Director Robert Stewart after completion of his current term, along with other matters (Key Developments).CIPLA: Pfizer Alliance And CEO Transition Will Shape Steady Forward Outlook
Analysts have kept their Cipla price target unchanged at ₹1,446.31, reflecting consistent assumptions on discount rate, revenue growth, profit margin and future P/E in their models. What's in the News Cipla has agreed to a 60:40 joint venture with Kemwell Biopharma in India to develop, obtain licenses for, manufacture, commercialise, import and export biologic products, with scope to license or outsource these activities (company announcement).CIPLA: Pfizer Tie-Up And Leadership Shift Will Shape Balanced Outlook
Analysts have trimmed their price target on Cipla by about ₹10 to reflect slightly softer assumptions around long term revenue growth and profit margins, while keeping the P/E framework broadly unchanged. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, including Corex Dx, Corex LS, Dolonex, Neksium and Dalacin C, while Pfizer continues to manufacture and supply these medicines (Key Developments).CIPLA: Pfizer Partnership And Upcoming Results Will Guide Balanced Future Expectations
Analysts have trimmed their price target for Cipla slightly to ₹1,456 from about ₹1,459, reflecting updated assumptions on discount rate, revenue growth, profit margin and future P/E that are broadly in line with prior views. What's in the News Pfizer India and Cipla entered into a partnership under which Cipla will exclusively market and distribute four Pfizer brands in India, covering Corex Dx and Corex LS cough syrups, Dolonex (NSAID), Neksium (PPI) and Dalacin C (oral antibiotic).CIPLA: Pfizer Alliance And Upcoming Results Will Shape Measured Future Upside Potential
Analysts have revised their fair value estimate for Cipla to ₹1,458.53, down from ₹1,657.58, citing updated assumptions for revenue growth, profit margins and future P/E multiples. What's in the News Cipla has scheduled a board meeting on Jan 23, 2026, at 11:00 Indian Standard Time to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended Dec 31, 2025 (company filing).Cipla Limited Just Missed EPS By 48%: Here's What Analysts Think Will Happen Next
The analysts might have been a bit too bullish on Cipla Limited ( NSE:CIPLA ), given that the company fell short of...The Market Doesn't Like What It Sees From Cipla Limited's (NSE:CIPLA) Earnings Yet
With a price-to-earnings (or "P/E") ratio of 20.7x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...CIPLA: Pfizer Partnership And Leadership Transition Will Support Future Upside Potential
Analysts have slightly reduced their fair value estimate for Cipla to ₹1,658 from ₹1,677, citing updated assumptions that combine modestly higher revenue growth expectations with some pressure on profit margins and a marginally adjusted future P/E multiple. What's in the News A board meeting is scheduled on January 23, 2026, to consider and approve unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025 (Key Developments).We Think Cipla (NSE:CIPLA) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Does Cipla (NSE:CIPLA) Deserve A Spot On Your Watchlist?
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...Analyst Estimates: Here's What Brokers Think Of Cipla Limited (NSE:CIPLA) After Its Second-Quarter Report
Cipla Limited ( NSE:CIPLA ) just released its latest quarterly results and things are looking bullish. Results were...Cipla Limited's (NSE:CIPLA) Prospects Need A Boost To Lift Shares
With a price-to-earnings (or "P/E") ratio of 22.9x Cipla Limited ( NSE:CIPLA ) may be sending bullish signals at the...Cipla (NSE:CIPLA) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Emerging Markets And Chronic Therapies Will Open New Horizons
With consensus forecasts for both revenue growth (8.4% p.a.) and net profit margin (15.92%) remaining steady, Cipla's Analyst Price Target was left unchanged at ₹1677. What's in the News Cipla is significantly expanding its US manufacturing capacity with an 83,000-square-foot addition at its Fall River, Massachusetts facility, focusing on complex respiratory products, and will utilize advanced technology to enhance production and efficiency.Here's Why Cipla (NSE:CIPLA) Has Caught The Eye Of Investors
Investors are often guided by the idea of discovering 'the next big thing', even if that means buying 'story stocks...
Aspirational Inhalation Launches And African Expansion Propel Growth Ambitions
Planned respiratory therapies and product launches could drive increased revenue and enhance the chronic therapy segment's growth.Aktionärsrenditen
| CIPLA | IN Pharmaceuticals | IN Markt | |
|---|---|---|---|
| 7D | 1.3% | 3.3% | 1.0% |
| 1Y | -3.6% | 12.6% | -1.4% |
Rendite im Vergleich zur Industrie: CIPLA unter dem Niveau der Branche Indian Pharmaceuticals , die im vergangenen Jahr eine Rendite von 12.6% erzielte.
Rendite vs. Markt: CIPLA hinter dem Markt Indian zurück, der im vergangenen Jahr eine Rendite von -1.4 erzielte.
Preisvolatilität
| CIPLA volatility | |
|---|---|
| CIPLA Average Weekly Movement | 3.8% |
| Pharmaceuticals Industry Average Movement | 6.6% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in IN Market | 9.3% |
| 10% least volatile stocks in IN Market | 4.1% |
Stabiler Aktienkurs: CIPLA hatte in den letzten 3 Monaten im Vergleich zum Indian -Markt keine signifikante Preisvolatilität.
Volatilität im Zeitverlauf: CIPLADie wöchentliche Volatilität (4%) ist im vergangenen Jahr stabil geblieben.
Über das Unternehmen
| Gegründet | Mitarbeiter | CEO | Website |
|---|---|---|---|
| 1935 | 31,369 | Achin Gupta | www.cipla.com |
Cipla Limited ist zusammen mit seinen Tochtergesellschaften in der Herstellung, der Entwicklung, dem Verkauf und dem Vertrieb von pharmazeutischen Produkten in Indien, den Vereinigten Staaten, Südafrika und international tätig. Das Unternehmen ist in den Segmenten Pharmazeutika und New Ventures tätig. Es bietet Generika und Markenmedikamente, Impfstoffe, pharmazeutische Wirkstoffe und Formulierungen für verschiedene therapeutische Bereiche, wie MI, Angina pectoris, Herzerkrankungen, Lungenerkrankungen, Nierenversagen, Alzheimer-Krankheit, Bluthochdruck, Herzrhythmusstörungen, Fettstoffwechselstörungen und Diabetes, Fettleibigkeit, zentrales Nervensystem, HIV/AIDS, Atemwegserkrankungen, Asthma, Urologie, Onkologie, Kardio-Metabolismus, Kindergesundheit, Infektionskrankheiten und Intensivmedizin, Hepatitis, Frauengesundheit, Augenheilkunde und Neuropsychiatrie.
Cipla Limited's Grundlagenzusammenfassung
| CIPLA grundlegende Statistiken | |
|---|---|
| Marktanteil | ₹1.18t |
| Gewinn(TTM) | ₹38.79b |
| Umsatz(TTM) | ₹278.28b |
Ist CIPLA zu teuer?
Siehe Fair Value und BewertungsanalyseErträge & Einnahmen
| CIPLA Gewinn- und Verlustrechnung (TTM) | |
|---|---|
| Einnahmen | ₹278.28b |
| Kosten der Einnahmen | ₹98.10b |
| Bruttogewinn | ₹180.18b |
| Sonstige Ausgaben | ₹141.39b |
| Gewinn | ₹38.79b |
Zuletzt gemeldete Gewinne
Mar 31, 2026
Datum des nächsten Gewinnberichts
Jul 23, 2026
| Gewinn per Aktie (EPS) | 48.02 |
| Bruttomarge | 64.75% |
| Nettogewinnspanne | 13.94% |
| Schulden/Eigenkapital-Verhältnis | 0.7% |
Wie hat sich CIPLA auf lange Sicht entwickelt?
Historische Performance und VergleicheDividenden
Zahlt CIPLA eine zuverlässige Dividende?
Siehe CIPLA Dividendenhistorie und Benchmarks| Cipla Dividendentermine | |
|---|---|
| Ex-Dividenden Datum | Jun 05 2026 |
| Datum der Dividendenzahlung | Jul 25 2026 |
| Tage bis Ex-Dividende | 30 days |
| Tage bis zum Datum der Dividendenzahlung | 20 days |
Zahlt CIPLA eine zuverlässige Dividende?
Siehe CIPLA Dividendenhistorie und BenchmarksUnternehmensanalyse und Finanzdaten Status
| Daten | Zuletzt aktualisiert (UTC-Zeit) |
|---|---|
| Unternehmensanalyse | 2026/07/04 09:40 |
| Aktienkurs zum Tagesende | 2026/07/03 00:00 |
| Gewinne | 2026/03/31 |
| Jährliche Einnahmen | 2026/03/31 |
Datenquellen
Die in unserer Unternehmensanalyse verwendeten Daten stammen von S&P Global Market Intelligence LLC. Die folgenden Daten werden in unserem Analysemodell verwendet, um diesen Bericht zu erstellen. Die Daten sind normalisiert, was zu einer Verzögerung bei der Verfügbarkeit der Quelle führen kann.
| Paket | Daten | Zeitrahmen | Beispiel US-Quelle * |
|---|---|---|---|
| Finanzdaten des Unternehmens | 10 Jahre |
| |
| Konsensschätzungen der Analysten | +3 Jahre |
|
|
| Marktpreise | 30 Jahre |
| |
| Eigentümerschaft | 10 Jahre |
| |
| Verwaltung | 10 Jahre |
| |
| Wichtige Entwicklungen | 10 Jahre |
|
* Beispiel für US-Wertpapiere, für nicht-US-amerikanische Wertpapiere werden gleichwertige regulatorische Formulare und Quellen verwendet.
Sofern nicht anders angegeben, beziehen sich alle Finanzdaten auf einen Jahreszeitraum, werden aber vierteljährlich aktualisiert. Dies wird als Trailing Twelve Month (TTM) oder Last Twelve Month (LTM) Daten bezeichnet. Erfahren Sie mehr.
Analysemodell und Schneeflocke
Details des Analysemodells, das zur Erstellung dieses Berichts verwendet wurde, sind auf unserer GitHub-Seite verfügbar. Außerdem haben wir Leitfäden zur Nutzung unserer Berichte und Tutorials auf YouTube.
Erfahren Sie mehr über das Weltklasse-Team, das das Simply Wall St-Analysemodell entworfen und entwickelt hat.
Metriken für Industrie und Sektor
Unsere Branchen- und Sektionskennzahlen werden alle 6 Stunden von Simply Wall St berechnet. Details zu unserem Verfahren finden Sie auf Github.
Analysten-Quellen
Cipla Limited wird von 54 Analysten beobachtet. 36 dieser Analysten hat die Umsatz- oder Gewinnschätzungen übermittelt, die als Grundlage für unseren Bericht dienen. Die von den Analysten übermittelten Daten werden im Laufe des Tages aktualisiert.
| Analyst | Einrichtung |
|---|---|
| Rohit Bhat | 360 ONE Capital Market Private Limited |
| Gaurav Tinani | Ambit Capital |
| null null | Anand Rathi Shares and Stock Brokers Limited |